Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that severe forms of alopecia areata were associated with significantly lower vitamin D levels compared to mild forms, suggesting vitamin D as a possible factor in disease severity.

This study found that severe forms of alopecia areata showed increased activated T cells and natural killer cells, which decreased after corticosteroid treatment, correlating with disease activity and hair regrowth.

Azathioprine may help with severe hair loss, a new topical treatment could counteract hair thinning, and trichoscopy can diagnose hair-pulling disorder effectively.

This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This study reports that baricitinib was effective and well-tolerated over 52 weeks for severe alopecia areata, with significant improvements in disease severity and no serious adverse events.

This study observed a high prevalence of severe markers among pediatric alopecia areata patients, identifying AA subtotalis as more frequent, with nail changes and various hair markers suggesting progression to severe forms.

This study reports two cases of severe alopecia areata showing seemingly permanent hair regrowth with a modified triamcinolone acetonide regimen involving epinephrine, and suggests a potential role for epinephrine in enhancing treatment efficacy.

In this study, patients with more severe self-reported hair loss and emotional or social limitations experienced lower quality of life and greater work productivity impairment, with even moderate hair loss causing significant well-being and daily activity impacts.

This study found that while 51.3% of severe alopecia areata patients achieved significant hair regrowth with intravenous methylprednisolone, oral Janus kinase inhibitors may benefit those who do not respond to this treatment.

This article discusses the emotional and psychological impact of severe alopecia areata on patients, emphasizing feelings of loss, vulnerability, and self-identity changes, and reports no new results.

This study found that hyperpigmentation following contact immunotherapy for severe alopecia areata may indicate poor treatment responsiveness and aligns with characteristics of pigmented contact dermatitis.

This study conducted in the Kingdom of Saudi Arabia reported that severe alopecia areata presents significant treatment challenges due to limited therapies, leading to substantial impacts on patients' quality of life, mental health, and economic burdens.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study of patients with moderate to severe alopecia areata in Morocco found that oral betamethasone mini-pulses yielded ≥50% hair regrowth in 62.5% of cases, improved quality of life scores, and were generally well-tolerated, though relapses and mild side effects were noted.

In this case report, significant hair regrowth was achieved in a young Filipino woman with severe diffuse alopecia areata using a combination of corticosteroids and methotrexate, highlighting the value of traditional therapies in regions with limited access to newer treatments.

This paper discusses a consensus statement from European experts recommending systemic JAK inhibitors as first-line therapy for moderate to severe alopecia areata.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

This study estimates that adding baricitinib to a commercial formulary for treating severe alopecia areata would slightly increase the budget by $1,383,345 over five years, with minimal impact per member per month.

This case report describes a patient with systemic sclerosis and severe alopecia areata who experienced complete resolution of hair loss within four months after treatment with topical steroids, minoxidil, and mycophenolate mofetil.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.

This genome-wide association study identified 20 genetic signals at 15 risk loci related to severe acne, revealing new insights into its genetic predisposition, particularly affecting skin structure and maintenance.

This review reports on new and effective drug developments for treating severe alopecia areata, including oral baricitinib, but emphasizes that no treatment guarantees permanent remission or works for all patients, with high recurrence rates after stopping medication.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This review highlights that JAK inhibitors have transformed severe alopecia areata treatment by disrupting disease signaling, emphasizing the need for strategies to address non-responders and manage treatment discontinuation.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

This study found that methotrexate may be an effective and safe treatment option for severe alopecia areata, with better regrowth results when combined with corticosteroids.